The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Early Detection of Ovarian Cancer
Open accessAbstract
Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological cancers. Less than 30% of women with advanced stage disease survive long‐term. When diagnosed in stage I, up to 90% of patients can be cured with conventional surgery and chemotherapy. At present, only 25% of ovarian cancers are detected in stage I due, in part, to the absence of specific symptoms and to lack of an effective screening strategy. Early detection of ovarian cancer might significantly improve the overall survival rate of women with ovarian cancer if 1) most cancers are clonal and unifocal, arising in the ovary rather than in the peritoneum, 2) metastatic disease results from progression of clinically detectable stage I lesions, and 3) cancers remain localized for a sufficient interval to permit cost‐effective screening. Given the prevalence of ovarian cancer, strategies for early detection must have high sensitivity for early stage disease (> 75%), but must have extremely high specificity (99.6%) to attain a positive predictive value of at least 10%. Transvaginal sonography (TVS), serum markers and a combination of the two modalities have been evaluated for early detection of ovarian cancer. Among the serum markers, CA125 has received the most attention, but lacks the sensitivity or specificity to function alone as a screening test. Greater specificity can be achieved by combining CA125 and TVS and/or by monitoring CA125 over time. Two stage screening strategies promise to be cost effective, where abnormal serum assays prompt TVS to detect lesions that require laparotomy. Accrual has been completed for a 200,000 woman trial in the United Kingdom that will test the ability of a rising CA125 to trigger TVS and subsequent exploratory surgery. Given the heterogeneity of ovarian cancer, it is unlikely that any single marker will be sufficiently sensitive to provide an effective initial screen. Sensitivity of serum assays might be enhanced by utilizing a panel of biomarkers. Candidate biomarkers have been discovered through empirical development of monoclonal antibodies, studies of gene expression, cloning of gene families and proteomic techniques. The development of technologies that measure multiple serum markers simultaneously, linked to the creation of statistical methods that enhance sensitivity without sacrificing specificity hold great promise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 934
Self-citationA candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
Hellström, I., Raycraft, J., Hayden-Ledbetter, M. S., Ledbetter, J. A., Schummer, M., McIntosh, M. W., Drescher, C. W., Urban, N. D., & Hellström, K. E. (2003) · PubMed · Cited by 711
Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers
Xu, Y. (1998) · JAMA · doi:10.1001/jama.280.8.719 · Cited by 637
Screening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
New tumor markers: CA125 and beyond
BAST, R. C., BADGWELL, D., LU, Z., MARQUEZ, R., ROSEN, D., LIU, J., BAGGERLY, K. A., ATKINSON, E. N., SKATES, S., ZHANG, Z., et al. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00441.x · Cited by 504
Self-citationHough, C. D., Sherman‐Baust, C. A., Pizer, E. S., Montz, F. J., Im, D. D., Rosenshein, N. B., Cho, K. R., Riggins, G. J., & Morin, P. J. (2000) · PubMed · Cited by 502
Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
Kim, J.-H. (2002) · JAMA · doi:10.1001/jama.287.13.1671 · Cited by 480
Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440
Self-citationSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Schummer, M., Ng, W. V., Bumgarner, R. E., Nelson, P. S., Schummer, B., Bednarski, D. W., Hassell, L., Baldwin, R. L., Karlan, B. Y., & Hood, L. (1999) · Gene · doi:10.1016/s0378-1119(99)00342-x · Cited by 402
Potential markers that complement expression of CA125 in epithelial ovarian cancer
Rosen, D. G., Wang, L., Atkinson, J. N., Yu, Y., Lu, K. H., Diamandis, E. P., Hellstrom, I., Mok, S. C., Liu, J., & Bast, R. C. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.06.040 · Cited by 385
Self-citationYamamoto, S., Konishi, I., Mandai, M., Kuroda, H., Komatsu, T., Nanbu, K., Sakahara, H., & Mori, T. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.537 · Cited by 356
Buys, S. S., Partridge, E., Greene, M. H., Prorok, P. C., Reding, D., Riley, T. L., Hartge, P., Fagerstrom, R. M., Ragard, L. R., Chia, D., et al. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.05.005 · Cited by 346
The Efficacy of Transvaginal Sonographic Screening in Asymptomatic Women at Risk for Ovarian Cancer
van Nagell, J. R., DePriest, P. D., Reedy, M. B., Gallion, H. H., Ueland, F. R., Pavlik, E. J., & Kryscio, R. J. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5816 · Cited by 345
Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G. E., Hellström, K. E., & Hellström, I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11531 · Cited by 344
Lysophospholipids Are Potential Biomarkers of Ovarian Cancer
Sutphen, R., Xu, Y., Wilbanks, G. D., Fiorica, J., Grendys, E. C., LaPolla, J. P., Arango, H., Hoffman, M. S., Martino, M., Wakeley, K., et al. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.1185.13.7 · Cited by 338
Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.
Xu, Y., Gaudette, D. C., Boynton, J., Frankel, A., Fang, X. J., Sharma, A., Hurteau, J. A., Casey, G., Goodbody, A., & Mellors, A. (1995) · PubMed · Cited by 322
Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology
Mok, S. C., Chao, J., Skates, S., Wong, K.-K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., & Cramer, D. W. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1458 · Cited by 320
Characterization of serum biomarkers for detection of early stage ovarian cancer
Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., Reddy, S., & Farias‐Eisner, R. (2005) · PROTEOMICS · doi:10.1002/pmic.200500093 · Cited by 311
Marquez, R. T., Baggerly, K. A., Patterson, A. P., Liu, J., Broaddus, R., Frumovitz, M., Atkinson, E. N., Smith, D. I., Hartmann, L., Fishman, D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2509 · Cited by 308
Self-citationMultiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer
Gorelik, E., Landsittel, D. P., Marrangoni, A. M., Modugno, F., Velikokhatnaya, L., Winans, M. T., Bigbee, W. L., Herberman, R. B., & Lokshin, A. E. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0404 · Cited by 264
Dubeau, L. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5275 · Cited by 262
High-resolution serum proteomic features for ovarian cancer detection.
Conrads, T. P., Fusaro, V. A., Ross, S., Johann, D., Rajapakse, V, Hitt, B. A., Steinberg, S. M., Kohn, E. C., Fishman, D. A., Whitely, G., et al. (2004) · Endocrine-related cancer · doi:10.1677/erc.0.0110163 · Cited by 260
Skates, S. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.955 · Cited by 256
Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer
Menon, U., Skates, S. J., Lewis, S., Rosenthal, A. N., Rufford, B., Sibley, K., MacDonald, N., Dawnay, A., Jeyarajah, A., Bast, R. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6642 · Cited by 243
Self-citationBourne, T. H., Campbell, S., Reynolds, K. M., Whitehead, M. I., Hampson, J., Royston, P., Crayford, T. J., & Collins, W. P. (1993) · BMJ · doi:10.1136/bmj.306.6884.1025 · Cited by 240
Salceda, S., Tang, T., Kmet, M., Munteanu, A., Ghosh, M., Macina, R., Liu, W., Pilkington, G., & Papkoff, J. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.01.018 · Cited by 217
Meinhold-Heerlein, I., Bauerschlag, D., Hilpert, F., Dimitrov, P., Sapinoso, L. M., Orlowska-Volk, M., Bauknecht, T., Park, T.-W., Jonat, W., Jacobsen, A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208298 · Cited by 205
Status of Tumor Markers in Ovarian Cancer Screening
Bast, R. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.068 · Cited by 204
Self-citationGenetic analysis of early- versus late-stage ovarian tumors.
Shridhar, V., Lee, J., Pandita, A., Iturria, S., Avula, R., Staub, J., Morrissey, M., Calhoun, E., Sen, A., Kalli, K., et al. (2001) · PubMed · Cited by 196
Self-citationCombining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma
McIntosh, M. W., Drescher, C., Karlan, B., Scholler, N., Urban, N., Hellstrom, K. E., & Hellstrom, I. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.039 · Cited by 193
Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells
Fang, X., Yu, S., Bast, R. C., Liu, S., Xu, H.-J., Hu, S.-X., LaPushin, R., Claret, F. X., Aggarwal, B. B., Lu, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306662200 · Cited by 192
Self-citationHuman kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma
Diamandis, E. P., Yousef, G. M., Soosaipillai, A. R., & Bunting, P. (2000) · Clinical Biochemistry · doi:10.1016/s0009-9120(00)00182-x · Cited by 176
Hayes, R. B., Reding, D., Kopp, W., Subar, A. F., Bhat, N., Rothman, N., Caporaso, N., Ziegler, R. G., Johnson, C. C., Weissfeld, J. L., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00101-x · Cited by 170
Skates, S. J., Horick, N., Yu, Y., Xu, F.-J., Berchuck, A., Havrilesky, L. J., de Bruijn, H. W. A., van der Zee, A. G. J., Woolas, R. P., Jacobs, I. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.091 · Cited by 170
Self-citationSchwartz, D. R., WU, R. T., Kardia, S. L. R., Levin, A. M., Huang, C.-C., Shedden, K., Kuick, R. D., Misek, D. E., Hanash, S., Taylor, J. M. G., et al. (2003) · PubMed · Cited by 170
Cancer diagnosis using proteomic patterns
Conrads, T. P., Zhou, M., III, E. F. P., Liotta, L., & Veenstra, T. D. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.4.411 · Cited by 164
Ye, B., Skates, S., Mok, S. C., Horick, N. K., Rosenberg, H. F., Vitonis, A., Edwards, D., Sluss, P., Han, W. K., Berkowitz, R. S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0461 · Cited by 162
B7-H4 overexpression in ovarian tumors
Tringler, B., Liu, W., Corral, L. G., Torkko, K. C., Enomoto, T., Davidson, S. A., Lucia, M. S., Heinz, D. E., Papkoff, J., & Shroyer, K. R. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.060 · Cited by 148
L’Espérance, S., Popa, I., Bachvarova, M., Plante, M., Patten, N., Wu, L., Têtu, B., & Bachvarov, D. R. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.5 · Cited by 145
Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer
Lokshin, A. E., Winans, M., Landsittel, D. P., Marrangoni, A., Velikokhatnaya, L., Modugno, F., Nolen, B. M., & Gorelik, E. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.011 · Cited by 144
Early Detection of Ovarian Cancer: Promise and Reality
Bast, R. C., Urban, N. D., Shridhar, V., Smith, D., Zhang, Z., Skates, S. J., Lu, K. H., Liu, J., Fishman, D. A., & Mills, G. B. (2002) · Cancer treatment and research · doi:10.1007/978-1-4757-3587-1_3 · Cited by 143
Self-citationOvarian cancer: Can we make the clinical diagnosis earlier?
Smith, L. H., Morris, C. R., Yasmeen, S., Parikh‐Patel, A., Cress, R. D., & Romano, P. S. (2005) · Cancer · doi:10.1002/cncr.21310 · Cited by 138
van Haaften‐Day, C., Shen, Y., Xu, F., Yu, Y., Berchuck, A., Havrilesky, L. J., de Bruijn, H. W. A., van der Zee, A. G. J., Bast, R. C., & Hacker, N. F. (2001) · Cancer · Cited by 110
Self-citationBignotti, E., Tassi, R. A., Calza, S., Ravaggi, A., Romani, C., Rossi, E., Falchetti, M., Odicino, F. E., Pecorelli, S. L., & Santin, A. D. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.056 · Cited by 109
Human kallikrein 10: a novel tumor marker for ovarian carcinoma?
Luo, L., Bunting, P. S., Scorilas, A., & Diamandis, E. P. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00401-6 · Cited by 106
Moore, L. E., Fung, E. T., McGuire, M., Rabkin, C., Molinaro, A. M., Wang, Z., Zhang, F., Wang, J., Yip, C., Meng, X., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0980 · Cited by 101
Manenti, L., Paganoni, P., Floriani, I., Landoni, F., Torri, V., Buda, A. A., Taraboletti, G., Labianca, R., Belotti, D., & Giavazzi, R. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00427-1 · Cited by 100
Mayr, D. C., Kanitz, V., Anderegg, B., Luthardt, B., Engel, J., Löhrs, U., Amann, G., & Diebold, J. (2006) · American Journal of Clinical Pathology · doi:10.1309/n6x5mb24bp42kp20 · Cited by 97
Place of Pattern in Proteomic Biomarker Discovery
Gillette, M. A., Mani, D. R., & Carr, S. A. (2005) · Journal of Proteome Research · doi:10.1021/pr0500962 · Cited by 86
Rosenthal, A. N., Menon, U., & Jacobs, I. J. (2006) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-200609000-00004 · Cited by 81
Zhang, Z., Barnhill, S. D., Zhang, H., Xu, F., Yu, Y., Jacobs, I. J., Woolas, R. P., Berchuck, A., Madyastha, K. R., & Bast, R. C. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5320 · Cited by 76
Self-citationBiomarker discovery for ovarian cancer using SELDI-TOF-MS
Zhang, H., Kong, B., Qu, X., Jia, L., Deng, B., & Yang, Q. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.11.029 · Cited by 71
High-resolution serum proteomic patterns for ovarian cancer detection
Baggerly, K., Edmonson, S. R., Morris, J. S., & Coombes, K. R. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00868 · Cited by 64
Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
Menon, U., Talaat, A. S., Jeyarajah, A., Rosenthal, A. N., MacDonald, N., Skates, S. J., Sibley, K., Oram, D. H., & Jacobs, I. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690575 · Cited by 61
Nap, M., Vitali, A., Nustad, K., et al. (1996) · Tumor Biology · doi:10.1159/000217996 · Cited by 57
New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope
O’Brien, T. J., Raymond, L. M., Bannon, G. A., Ford, D. H., Harðardóttir, H., Miller, F. C., & Quirk, J. G. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90046-t · Cited by 56
Plasma proteomic pattern as biomarkers for ovarian cancer
Lin, Y., Lin, C., Lai, H., CHIOU, J.-Y., Chang, C., Yu, M., & Chu, T. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00475.x · Cited by 53
Detecting and aligning peaks in mass spectrometry data with applications to MALDI
Yu, W., Wu, B., Lin, N., Stone, K. L., Williams, K. R., & Zhao, H. (2005) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2005.10.006 · Cited by 52
Page, C. L., Ouellet, V., Madore, J., Ren, F., Hudson, T. J., Tonin, P. N., Provencher, D. M., & Mes‐Masson, A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602933 · Cited by 50
Temperature Range of Thermodynamic Stability for the Native State of Reversible Two-State Proteins
Kumar, S., Tsai, C. J., & Nussinov, R. (2003) · Biochemistry · doi:10.1021/bi027184+ · Cited by 44
Artificial neural network computer prediction of ovarian malignancy in women with adnexal masses
Szpurek, D., Moszyński, R., Smoleń, A., & Sajdak, S. (2005) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2005.01.034 · Cited by 28
Moscova, M., Marsh, D. J., & Baxter, R. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2666 · Cited by 28
Moszyński, R., Szpurek, D., Smoleń, A., & Sajdak, S. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00277.x · Cited by 27
The role of gene expression profiling in the clinical management of ovarian cancer
Olivier, R. I., van Beurden, M., & Veer, L. V. ‘. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.04.013 · Cited by 21
Cited by
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
Sant, M., Allemani, C., Santaquilani, M., Knijn, A., Marchesi, F., & Capocaccia, R. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.018 · Cited by 1,021
Ovarian cancer in the world: epidemiology and risk factors
Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019) · International Journal of Women's Health · doi:10.2147/ijwh.s197604 · Cited by 912
Hennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Sensing of proteins in human serum using conjugates of nanoparticles and green fluorescent protein
De, M., Rana, S., Akpinar, H., Miranda, O. R., Arvizo, R. R., Bunz, U. H. F., & Rotello, V. M. (2009) · Nature Chemistry · doi:10.1038/nchem.334 · Cited by 488
Application of Nanotechnology in Cancer Diagnosis and Therapy - A Mini-Review
Jin, C., Wang, K., Oppong-Gyebi, A., & Hu, J. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.49801 · Cited by 353
Metadata
- Authors
- Badgwell, D., & Bast, R. C.
- Venue
- Disease Markers
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 23
- Issue
- 5-6
- Pages
- 397-410
- ISSN
- 0278-0240 (ISSN-L)
- 1875-8630
- OpenAlex
- W2118656195
- Cited by
- 294
- References
- 68
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.